Safety outcomes of intravitreal implant of fl uocinolo | 56687
Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

Safety outcomes of intravitreal implant of fl uocinolone acetonide 0.19 mg in clinical practice assessed by intraocular pressure measurement

17th Global Ophthalmology, Glaucoma and Optometry Conference

November 02-04, 2017 Bangkok, Thailand

Jose Antonio Dias

Clinical Director, Malo Clinic, Portugal.

Keynote: J Clin Exp Ophthalmol

Abstract :

Aim: Th e use of intravitreal corticosteroids (IVT) in the treatment of diabetic macular edema (DME) increased in recent years. It is a common complication of intravitreal steroids in secondary ocular hypertension (OHT), which can occur immediately as a consequence of increased intraocular volume or later due to increased outfl ow resistance. Most cases of OHT are clinically manageable. Th e aim of this study was to determine rise of intraocular pressure (IOP) in DME patients treated with fl uocinolone acetonide (FAc) 0.19 mg intravitreal injection. Methods: 107 FAc-treated eyes of 92 diabetic patients with chronic DME were analyzed retrospectively. IOP was assessed at baseline, week 2-4, month 3, month 6, month 9 and 1 year aft er FAc implantation. All patients included in this study, which adhered to the tenets of the Declaration of Helsinki, gave their informed consent. Results: At baseline mean IOP was 15.59?±3.50 mmHg (mean?±standard deviation). At week 2-4, month 1, 3, 6, 9 and month 12 it was observed an IOP value of 16.37?±4.06 mmHg (mean?±standard deviation), 17.61?±4.87 mmHg (mean?±standard deviation), 16.19?±3.81 mmHg (mean?±standard deviation), 18.00?±4.63 mmHg (mean?±standard deviation), and 18.00?±5.20 mmHg (mean?±standard deviation), respectively (p<0.0001). Th e mean IOP change from baseline to 3, 6, 9 months and 1 year was 0.8, 2.1, 0.8, 2.2 and 1.9 mmHg, respectively. At baseline, 75% of patients reported as not taking IOP lowering medication vs. 25% of patients who were already taking medication for this indication. At the end of the 12-month follow-up, 15% of the patients started IOP lowering medication. No patients required incisional surgery for OHT. Conclusions: In our study, most of the eyes treated with FAc implant remained controlled, with no signifi cant concerns due to IOP changes. About 15% of the patients started IOP lowering medication aft er implantation which is lower than the reported 18.4% of the IRISS study and 22.0% of the FAME study. Th ese results appear to be in line with other IOP results observed in clinical practice in Europe and below the results reported in FAME studies, with lower IOP increase and a lower surgical rate. Steroid-induced OHT should not be considered a problem as long as patients remain correctly monitored and treated.

Biography :

Jose Antonio Dias was born on June 11, 1966 , in Caracas , Venezuela. Graduated from the Faculty of Medicine, University of Coimbra - Portugal, completed his training as an ophthalmologist at the Institute of Ophthalmology Dr. Gama Pinto – Lisbon - Portugal, being accepted as a member of the College of Ophthalmology in 1997.He participated in 192 research and scientifi c presentatins (141 as lead author), and co-authored three books devoted to glaucoma. He participated in a variety of scientifi c training courses aimed at ophthalmologists (252), residents formation (48), health technicians (16) and public enlightenment and social media sessions (currently keeps a monthly collaboration with national television to present issues related to eye health) .Currently performs his medical activity in Malo Clinic (where is Clinical Director), in Joaquim Chaves Health Group (which is the coordinator of the Department of Ophthalmology) and CUF Hospital, working in consultation, diagnostics, surgery and medical education. Provides technical advice to several companies linked to the health area and still in regulatory institutions. Its main area of interest is the study of glaucoma, which has dedicated his research activity and scientifi c dissemination to the following fi elds:
• basic science and glaucoma • early diagnosis • risk indicators • compliance and persistence